McKesson Stock Price, News & Analysis

McKesson Corporation (NYSE: MCK) announced its fiscal 2022 third-quarter financial results. Investors can access detailed results through the company's Investor Relations website. A live webcast of the earnings conference call will be held on February 2 at 4:30 PM ET, where management will discuss financial performance. McKesson has been recognized as a leading healthcare supply chain management provider and is noted for its commitment to patient health through innovative healthcare solutions.

The Board of Directors of McKesson Corporation (NYSE:MCK) declared a regular dividend of 47 cents per share, set for payment on April 1, 2022, to stockholders of record on March 1, 2022. McKesson, a leader in healthcare supply chain management, emphasizes its commitment to providing essential healthcare services. Recognized as a top company in various categories, McKesson continues to enhance its reputation and investor confidence through consistent dividend payments.

McKesson Corporation (NYSE: MCK) announced the election of James H. Hinton and Kathleen Wilson-Thompson as new board directors on Jan. 13, 2022, increasing the board from 9 to 11 members. Hinton, an operating partner at Welsh, Carson, Anderson & Stone, previously served as CEO of Baylor Scott & White Health, while Wilson-Thompson was EVP and global chief human resources officer at Walgreens Boots Alliance. Their extensive healthcare leadership experience is expected to strengthen McKesson's governance and strategic direction.

McKesson Corporation (NYSE: MCK) will announce its third quarter fiscal 2022 financial results on February 2, 2022, after market close. A live webcast will follow at 4:30 PM ET to discuss the results. McKesson will also participate in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022. Investors can access the webcast and related financial information on McKesson’s Investor Relations website.

AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) have extended the deadline for political subdivisions to join the proposed opioid settlement from January 2, 2022, to January 26, 2022. New Mexico confirmed its participation, raising total states in the settlement to 43, covering all U.S. territories and Washington, D.C. The deadline to assess sufficient participation has also been moved from February 1, 2022, to February 25, 2022. The companies aim to expedite relief to affected communities and remain committed to addressing the opioid crisis.

McKesson Corporation (NYSE: MCK) has agreed to sell its Austrian operations to Quadrifolia Management GmbH. This deal includes McKesson Austria’s Herba Chemosan Apotheker-AG and Sanova Pharma GesmbH, expected to close in fiscal 2022 following regulatory approvals. CEO Brian Tyler stated this aligns with McKesson's strategy to streamline its portfolio and exit the European market, following previous agreements in the UK, France, Italy, Ireland, Portugal, Belgium, and Slovenia.

McKesson Corporation (NYSE: MCK) is hosting an Investor Day at 1:00 p.m. ET today to outline its strategy for sustainable growth. The event will cover progress in healthcare services and reaffirm commitments to expanding oncology and biopharma services. McKesson increased its fiscal 2022 Adjusted Earnings per Diluted Share guidance to $22.35-$22.95, boosted by the U.S. government's COVID-19 vaccine program. Additionally, a $4.0 billion share repurchase program was announced, highlighting a focus on shareholder value.

McKesson Corporation (NYSE: MCK) is set to host an Investor Day on December 8, 2021, from 1:00 PM to 4:00 PM ET in New York City. The event will include presentations by the leadership team, a live Q&A with CEO Brian Tyler and CFO Britt Vitalone, and discussions on the company’s progress towards sustainable growth and long-term financial outlook.

A video webcast will be available live and archived on McKesson's Investor Relations website.

Walgreens Boots Alliance (WBA) has announced its agreement to acquire the remaining 30% share of its joint venture with McKesson Corporation (MCK) in Germany, making WBA the sole owner of GEHE Pharma Handel and Alliance Healthcare Deutschland. This acquisition is part of McKesson's strategy to fully exit the European market. The transaction's financial terms were not disclosed and are subject to regulatory approval. This move aims to strengthen WBA's presence in the German pharmaceutical distribution market.